Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature

Miriam Dibos, Johanna Dumoulin, Carolin Mogler, Silke Wunderlich, Maximilian Reichert, Sebastian Rasch, Roland M. Schmid, Marc Ringelhan, Ursula Ehmer, Tobias Lahmer

Research output: Contribution to journalArticlepeer-review

Abstract

Nivolumab is a promising monoclonal antibody inhibitor of programmed death-1, a protein on the surface of T-cells. As such, it is approved for use in patients with multiple advanced malignancies and can significantly elongate progression-free survival. However, monoclonal antibody inhibitors can lead to adverse hepatic reactions, which in rare cases result in further hepatic damage. Herein, we present a case of a patient with locally advanced gastric carcinoma treated with fluorouracil, oxaliplatin, docetaxel and the checkpoint inhibitor nivolumab. Five months after her first dosage of nivolumab and without a preexisting liver disease, she presented with transaminitis. During the course of her stay, the patient developed status epilepticus, which required mechanical ventilation followed by fulminant hepatic failure. A subsequent liver biopsy revealed severe liver damage with extensive confluent parenchymal necrosis corresponding to checkpoint-inhibitor-induced hepatitis. Alternative reasons for this hepatic failure were ruled out. Despite aggressive therapeutic interventions including corticosteroids and plasma exchange, the patient died due to liver failure. Although hepatic failure is rarely seen in patients with checkpoint inhibitor therapy, it requires early awareness and rapid intervention.

Original languageEnglish
Article number4641
JournalJournal of Clinical Medicine
Volume12
Issue number14
DOIs
StatePublished - Jul 2023
Externally publishedYes

Keywords

  • checkpoint inhibitor
  • encephalitis
  • hepatic failure
  • nivolumab

Fingerprint

Dive into the research topics of 'Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature'. Together they form a unique fingerprint.

Cite this